UBT251 – BiotechReality – Information Intelligence System for Biopharma

UBT251 triple agonist investigational therapy jointly developed by United Biotechnology and Novo Nordisk that simultaneously activates receptors for GLP-1, GIP, and glucagon, has delivered compelling phase 2 results in Chinese patients with type 2 diabetes, with the highest-dose group achieving a mean glycated haemoglobin (HbA1c) reduction of 2.16 percentage points after 24 weeks. This marks a significant turning point for the so-called "triple G" class of metabolic agents and positions UBT251 as a potential best-in-class option for both glycaemic control and weight management. The topline data reveal that UBT251 outperformed both the active comparator semaglutide 1 mg, a globally established GLP-1 receptor agonist, and placebo across the primary and key secondary endpoints in the trial. The results add to an accelerating body of evidence suggesting that broader receptor co-stimulation may unlock therapeutic benefits that monotherapy cannot easily achieve. What Is the UBT251 Triple Agonist? Understanding the Science The UBT251 triple agonist is designed to simultaneously engage three distinct hormonal receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-G approach distinguishes UBT251 from earlier-generation therapies. GLP-1 agonists like semaglutide (Ozempic/Wegovy) and dual GLP-1/GIP agonists like tirzepatide (Mounjaro) have already demonstrated substantial clinical impact; adding glucagon receptor activation is hypothesised to further enhance weight reduction by increasing energy expenditure and promoting fat breakdown. According to the clinical framework, the glucagon component is carefully balanced to avoid the hyperglycaemia traditionally associated with glucagon signalling, while working synergistically with the incretin arms of the molecule to amplify cardiometabolic benefits. UBT251 is administered via a once-weekly subcutaneous injection, maintaining the convenience profile of leading GLP-1 therapies at doses of 2 mg, 4 mg, and 6 mg. For a deeper understanding of incretin-based therapies and their mechanisms, the National Library of Medicine's review of GLP-1 and GIP receptor agonism provides a robust background on the receptor biology involved. Read More: Novo Nordisk Unveils Groundbreaking Semaglutide & CagriSema Data, Reshaping Obesity & Diabetes Treatment Phase 2 Trial Design: UBT251 Triple Agonist vs. Semaglutide and Placebo The Chinese phase 2 trial enrolled adults with type 2 diabetes, enrolling participants with a baseline mean HbA1c of 8.12%, a baseline mean body weight of 80.1 kg, and a mean BMI of 29.1 kg/m² a phenotype characteristic of the Asian diabetes population, where glycaemic burden tends to occur at lower BMI thresholds compared to Western cohorts. The study was conducted exclusively by United Biotechnology, which holds development and commercialisation rights for mainland China, Hong Kong, Macau, and Taiwan under the March 2025 collaboration agreement with Novo Nordisk. Participants were randomised to once-weekly injectable UBT251 at 2 mg, 4 mg, or 6 mg doses, or to semaglutide 1 mg, or to placebo, over a 24-week treatment period. The co-primary endpoints included mean change in HbA1c and mean percentage change in body weight from baseline. UBT251 Triple Agonist Efficacy: A Head-to-Head Comparison Treatment ArmMean HbA1c ReductionMean Body Weight ReductionUBT251 (Best Dose)−2.16%−9.8%Semaglutide 1 mg−1.77%−4.8%Placebo−0.66%−1.4% The magnitude of HbA1c reduction 0.39 percentage points more than semaglutide, is clinically meaningful. Current guidelines from organisations such as the American Diabetes Association (ADA) and the European Association for the Study of Diabetes emphasise that incremental HbA1c reductions at the 0.3–0.5% level translate to reduced risks of microvascular complications, including diabetic nephropathy and retinopathy. BiotechReality JobFinder - Featured Posts The body weight reduction of 9.8% in 24 weeks is equally striking. This is more than double the 4.8% seen with semaglutide 1 mg in the same trial, and approaches the magnitude of benefit seen with higher-dose semaglutide formulations (Wegovy 2.4 mg) in dedicated obesity trials, though direct cross-trial comparisons must be interpreted cautiously given differing populations and protocols. Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment Secondary Endpoints: Beyond HbA1c and Weight The UBT251 triple agonist also demonstrated statistically significant improvements versus placebo on key cardiometabolic secondary endpoints. These include reductions in waist circumference a marker closely linked to visceral adiposity and cardiovascular risk, as well as improvements in blood pressure and a favourable shift in lipid profiles, including changes in triglycerides and LDL-cholesterol. These secondary findings suggest that UBT251's benefits extend beyond purely glycaemic control, pointing to a broader cardiometabolic effect consistent with the theoretical advantages of glucagon receptor co-agonism. The cardiovascular implications are particularly relevant given that type 2 diabetes is a major independent risk factor for cardiovascular disease. Physicians and payers are increasingly evaluating therapies not just on HbA1c reduction but on their ability to reduce total cardiovascular burden, a factor that has benefited drugs like semaglutide in regulatory and formulary discussions. Read More: Lilly’s Oral GLP-1 Orforglipron Shows Significant Weight Loss in Phase 3 ATTAIN-1 Trial Safety and Tolerability of the UBT251 Triple Agonist Safety is a critical consideration for any novel multi-receptor agonist, given the potential for off-target effects associated with glucagon activation. The trial investigators reported that the safety and tolerability profile of the UBT251 triple agonist appeared consistent with other triple-G agonists evaluated in clinical trials. This broadly implies a gastrointestinal adverse event profile, with nausea, vomiting, and diarrhoea being the most commonly reported events in this drug class, which is largely comparable to single and dual GLP-1 agonists, without evidence of excessive glucagon-driven hyperglycaemia. Detailed safety data will be presented by United Biotechnology at a medical congress later in 2026, at which point the full dataset, including dose-response relationships, adverse event rates by severity, and any notable outliers, will be available for the scientific community to scrutinise. For context on how safety profiling works in this class of drugs, the WHO diabetes overview offers useful background on treatment safety considerations. What This Means for Patients With Type 2 Diabetes For the estimated 537 million adults living with diabetes worldwide a figure the International Diabetes Federation projects will rise to 783 million by 2045, the development of more effective pharmacological tools remains urgent. The UBT251 triple agonist phase 2 results suggest that, if the safety and efficacy profile holds through phase 3, patients could have access to a therapy that offers meaningfully better glycaemic control and approximately twice the weight reduction compared to widely used semaglutide doses. Critically, the trial was conducted in a Chinese population, whose metabolic profile, including lower BMI thresholds for obesity-related complications, greater propensity for beta-cell dysfunction, and a high prevalence of visceral adiposity is distinct from Western cohorts. The fact that UBT251 achieved significant results in this population is clinically valuable on its own terms, and also increases confidence that the therapy's mechanism is broadly applicable across ethnicities. Novo Nordisk Last Modified:

Tag: UBT251

Novo Nordisk’s UBT251 Triple Agonist Achieves Landmark 2.16% HbA1c Reduction in Type 2 Diabetes Phase 2 Trial

Areas Covered

Discover More

Pfizer and Valneva Announce Strong Efficacy for Lyme Disease Vaccine Candidate

Novo Nordisk’s UBT251 Triple Agonist Achieves Landmark 2.16% HbA1c Reduction in Type 2 Diabetes Phase 2 Trial

Novartis Immunology Data at AAD 2026: Rhapsido and Cosentyx Results

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide